Osiris (NASDAQ:OSIR) Reports Positive Study Results for Prochymal – Video

Posted: Published on December 14th, 2011

This post was added by Dr. Richardson



2/24/2010-Osiris Therapeutics (NASDAQ:OSIR) said Wednesday according to its most recent study of 52 heart-attack patients, its stem cell therapy Prochymal improved cardiac function and reduced irregular heartbeats compared to a control group. Additionally, a larger Phase II study is underway on patients who have had severe heart attacks

Visit link:
Osiris (NASDAQ:OSIR) Reports Positive Study Results for Prochymal - Video

Related Posts
This entry was posted in Mesenchymal Stem Cells. Bookmark the permalink.

Comments are closed.